Document Type

Article

Publication Date

3-29-2023

Comments

This article is the author's final published version in Diagnostic and Interventional Radiology, Volume 29, Issue 2, March 2023, Pages 359 - 366.

The published version is available at https://doi.org/10.4274/dir.2023.221930.

Copyright © Author(s) - Available online at dirjournal.org. Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Abstract

PURPOSE: The purpose of this study was to analyze and compare the outcomes of percutaneous microwave ablation (MWA) when used as a primary vs. secondary treatment for hepatocellular carcinoma (HCC).

METHODS: The clinical data of 192 patients with HCC treated with MWA between January 2012 and July 2021 were reviewed retrospectively, with 152 patients being treatment naïve (primary treatment) vs. 40 who had residual or recurrent disease following previous trans-arterial chemoembolization or trans-arterial radioembolization (secondary treatment). The primary outcomes were primary technical efficacy, 1- and 3-year local recurrence-free survival (RFS) and overall survival (OS), local recurrence rates, and adverse events. Pre- and post-intervention liver function tests were compared using a Wilcoxon signed rank test. Univariate and multivariate analyses were also performed, looking at prognostic factors associated with OS and local RFS.

RESULTS: There was no significant difference in 1-year local RFS (primary 93.6% vs. secondary 93.7;

CONCLUSION: Microwave ablation is safe and effective as a secondary treatment for patients with HCC in a clinical salvage scenario and should be utilized more frequently.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

PubMed ID

36988024

Language

English

Download

Included in

Radiology Commons

Share

COinS